Clinical Trial Update: Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating donepezil for cognitive dysfunction in children with Down syndrome was terminated; results posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• Aricept (Donepezil)

Snippet

Sponsor: Eisai Inc. | Conditions: Down Syndrome, Cognitive Dysfunction | Phase 3 | Status: TERMINATED | Results posted: 2013-02-13